Association Between Glycemic Control and Diabetic Peripheral Neuropathy Among Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Analytical Study
DOI:
https://doi.org/10.61919/jhrr.v6i5.2007Keywords:
Diabetes mellitus; diabetic peripheral neuropathy; glycemic control; HbA1c; chronic kidney disease; neuropathy severity; cross-sectional study.Abstract
Background: Diabetic peripheral neuropathy is one of the most common microvascular complications of diabetes mellitus and is associated with substantial morbidity, impaired quality of life, and increased risk of foot ulceration and lower-limb amputation. Chronic hyperglycemia, prolonged disease duration, and associated metabolic comorbidities contribute to progressive peripheral nerve damage and worsening neurological dysfunction. Objective: To determine the association between glycemic control and diabetic peripheral neuropathy and to identify clinical predictors of poor neuropathic outcomes among patients with diabetes mellitus. Methods: This cross-sectional analytical study was conducted at the University of Lahore Teaching Hospital and included 206 patients with diabetes mellitus. Demographic, biochemical, and clinical variables including HbA1c, duration of diabetes, body mass index, blood pressure, fasting glucose, chronic kidney disease, hypertension, smoking status, vibration perception, and monofilament test findings were assessed. Logistic regression analysis was performed to estimate odds ratios and 95% confidence intervals for predictors of poor clinical outcome. Results: The mean age of participants was 54.8 ± 12.6 years, and the mean HbA1c level was 8.4 ± 1.7%. Poor glycemic control (HbA1c ≥7.0%) was present in 70.9% of participants and was significantly associated with poor clinical outcomes (OR 2.84, 95% CI 1.52–5.31, p=0.001). Each 1% increase in HbA1c increased the odds of poor neuropathic outcome by 42% (OR 1.42, 95% CI 1.18–1.71, p<0.001). Diabetes duration ≥10 years (OR 2.36, 95% CI 1.32–4.21, p=0.004) and chronic kidney disease (OR 1.91, 95% CI 1.02–3.59, p=0.043) were also significantly associated with adverse neuropathic outcomes. Reduced vibration perception and abnormal monofilament test findings were significantly more common among patients with poor outcomes (p<0.001). Conclusion: Poor glycemic control, prolonged diabetes duration, and chronic kidney disease were significant predictors of diabetic peripheral neuropathy and adverse neuropathic outcomes. Early neuropathy screening and optimization of glycemic control may help reduce progression of neurological complications in diabetic patients.
Downloads
References
Bondar A, Popa A, Papanas N, Popoviciu M, Vesa C, Sabau M, et al. Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options. Exp Ther Med. 2021;22(6):1428. doi:10.3892/etm.2021.10122
Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021;17(7):400-420. doi:10.1038/s41574-021-00496-z
Savelieff MG, Elafros M, Viswanathan V, Jensen TS, Bennett DL, Feldman EL. The global and regional burden of diabetic peripheral neuropathy. Nat Rev Neurol. 2024;20(5):289-303. doi:10.1038/s41582-024-01041-y
Calcutt N. Diabetic neuropathy and neuropathic pain: A (con)fusion of pathogenic mechanisms? Pain. 2020;161(Suppl 1):S65-S86. doi:10.1097/j.pain.0000000000001922
Galiero R, Caturano A, Vetrano E, Beccia D, Brin C, Alfano M, et al. Peripheral neuropathy in diabetes mellitus: Pathogenetic mechanisms and diagnostic options. Int J Mol Sci. 2023;24(4):3554. doi:10.3390/ijms24043554
American Diabetes Association. Standards of medical care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1-S350.
Gibbons C. Diabetes and metabolic disorders and the peripheral nervous system. Continuum. 2020;26(5):1283-1303. doi:10.1212/CON.0000000000000906
Yang H, Sloan G, Ye Y, Wang S, Duan B, Tesfaye S, Gao L. New perspective in diabetic neuropathy: From the periphery to the brain, a call for early detection, and precision medicine. Front Endocrinol (Lausanne). 2020;10:929. doi:10.3389/fendo.2019.00929
Zilliox L. Diabetes and peripheral nerve disease. Clin Geriatr Med. 2021;37(2):253-267. doi:10.1016/j.cger.2020.12.001
Nozawa K, Ikeda M, Kikuchi S. Association between HbA1c levels and diabetic peripheral neuropathy: A case-control study of patients with type 2 diabetes using claims data. Drugs Real World Outcomes. 2022;9(1):45-52. doi:10.1007/s40801-022-00309-3
Braffett BH, Gubitosi-Klug RA, Albers JW, Feldman EL, Martin CL, White NH, et al. Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the DCCT/EDIC study. Diabetes. 2020;69(5):1000-1010. doi:10.2337/db19-1046
Pinto MV, Pinto LF, Rosa LCGF, Dantas J, Salles GF, Lima MA, et al. HbA1c variability and long-term glycemic control are linked to peripheral neuropathy in patients with type 1 diabetes. Diabetol Metab Syndr. 2020;12:85. doi:10.1186/s13098-020-00594-4
Pfannkuche A, Alhajjar A, Ming A, Walter I, Piehler C, Mertens P. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative “diabetes and nerves”. Endocr Metab Sci. 2020;1:100052. doi:10.1016/j.endmts.2020.100053
Billa MS, Sulistiawan A, Subandi A. Relationship between glycemic control and duration of diabetes with diabetic peripheral neuropathy incidence. Mahesa Malahayati Health Student Journal. 2023;3(6):1672-1681. doi:10.33024/mahesa.v3i6.10443
Mizokami-Stout KR, Li Z, Foster N, Shah V, Aleppo G, McGill J, et al. The contemporary prevalence of diabetic neuropathy in type 1 diabetes: Findings from the T1D Exchange. Diabetes Care. 2020;43(4):806-812. doi:10.2337/dc19-1583
Mayeda L, Katz R, Ahmad I, Bansal N, Batacchi Z, Hirsch I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. doi:10.1136/bmjdrc-2019-000991
Elafros M, Andersen H, Bennett D, Savelieff MG, Viswanathan V, Callaghan B, Feldman EL. Towards prevention of diabetic peripheral neuropathy: Clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022;21(10):922-936. doi:10.1016/S1474-4422(22)00188-0
Yang K, Wang Y, Li YW, Chen YG, Xing N, Lin HB, et al. Progress in the treatment of diabetic peripheral neuropathy. Biomed Pharmacother. 2022;148:112717. doi:10.1016/j.biopha.2022.112717
Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X, et al. Diabetic peripheral neuropathy: Pathogenetic mechanisms and treatment. Front Endocrinol (Lausanne). 2024;14:1265372. doi:10.3389/fendo.2023.1265372
Yang Y, Zhao B, Wang Y, Lan H, Liu X, Hu Y, Cao P. Diabetic neuropathy: Cutting-edge research and future directions. Signal Transduct Target Ther. 2025;10(1):75. doi:10.1038/s41392-025-02175-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ajneeha Fatima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Public Licensing Terms
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license:
- You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, including commercial use.
- Attribution must be given to the original author(s) and source in a manner that is reasonable and does not imply endorsement. If changes were made to the material, this must be indicated.
- No additional restrictions may be applied that conflict with the terms of this license.
For more details, visit: https://creativecommons.org/licenses/by/4.0/
